1. Home
  2. |Insights
  3. |ACI - Biosimilars: The Definitive Forum on the Legal, Regulatory, Patent, and Commercial Realities of Biosimilars

ACI - Biosimilars: The Definitive Forum on the Legal, Regulatory, Patent, and Commercial Realities of Biosimilars

Event | 06.05.14 - 06.06.14, 12:00 AM UTC - 12:00 AM UTC

Attend the premier event where the industry leaders from both branded and biosimilar companies convene to formulate solutions to the complex regulatory and patent challenges ahead as the first wave of biosimilars become a reality in the U.S.


James Stronski is speaking on the topic "Timing is Everything: Managing the Logistics of the BPCIA Exchange Process and Preparing for "Early" and "Late" Phase Litigation."  Terry Rea is the Moderator on the topic "The Most Powerful Tool in Your Arsenal: Using Inter-Partes Review at the PTO to Revamp Branded and Biosimilar Litigation Strategies."


For more information, please visit these areas: Intellectual Property, Litigation and Trial, Intellectual Property Litigation

Insights

Event | 12.04.25

ACI 30th Annual Conference on Drug & Medical Device Litigation

Dan Campbell with Speak on the panel "Mastering MDL Case Management: What Proposed Rule 16.1 Really Means for Consolidated Litigation."
Rule 16.1 attempts to guide early case management in MDLs, impacting litigation pace and costs. Permissive language like “should” instead of “must”, could lead to inconsistent applications. This panel will explore the rule’s anticipated impact and implications for procedures.